Shattuck Labs (STTK) Cash & Equivalents (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Cash & Equivalents of $90.4 million for Q1 2026, up 48.48% year-over-year from $60.9 million in Q1 2025, and up 66.85% quarter-over-quarter from $54.2 million in Q4 2025.
Shattuck Labs (STTK) Cash & Equivalents (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Cash & Equivalents for 8 consecutive years, with $90.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 48.48% year-over-year to $90.4 million; the TTM figure through Mar 2026 stood at $90.4 million (up 48.48% YoY), while the FY2025 annual figure was $54.2 million, down 5.57% from the prior year.
- Cash & Equivalents grew to $90.4 million in Q1 2026 per STTK's latest filing, from $54.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $125.6 million in Q4 2023 and bottomed at $37.9 million in Q2 2022.
- Historically, Cash & Equivalents has averaged $59.8 million across 5 years, with a median of $54.2 million in 2025.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 56.22% — and 2023, when it surged 165.15%.
- Shattuck Labs' Cash & Equivalents stood at $47.4 million in 2022, then soared by 165.15% to $125.6 million in 2023, then tumbled by 54.32% to $57.4 million in 2024, then fell by 5.57% to $54.2 million in 2025, then surged by 66.85% to $90.4 million in 2026.
- Business Quant data shows STTK's Cash & Equivalents at $90.4 million in Q1 2026, $54.2 million in Q4 2025, and $42.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 63.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.30 Mn |
| Mar 31, 2026 | 90.42 Mn |
| Dec 31, 2025 | 54.19 Mn |
| Sep 30, 2025 | 42.55 Mn |
| Jun 30, 2025 | 50.47 Mn |
| Mar 31, 2025 | 60.90 Mn |
| Dec 31, 2024 | 57.39 Mn |
| Sep 30, 2024 | 43.83 Mn |
| Jun 30, 2024 | 60.69 Mn |
| Mar 31, 2024 | 76.01 Mn |
| Dec 31, 2023 | 125.63 Mn |
| Sep 30, 2023 | 40.63 Mn |
| Jun 30, 2023 | 71.89 Mn |
| Mar 31, 2023 | 66.04 Mn |
| Dec 31, 2022 | 47.38 Mn |
| Sep 30, 2022 | 39.76 Mn |
| Jun 30, 2022 | 37.87 Mn |
| Mar 31, 2022 | 50.74 Mn |
| Dec 31, 2021 | 92.27 Mn |
| Sep 30, 2021 | 85.09 Mn |